![]() |
FDA approves tisagenlecleucel (Kymriah ™): first gene...
October 1, 2017 - Featured , In the News / Politics By: Anna Diyamandoglu, PharmD Candidate c/o 2020 – The specificity of individuals’ genetic makeup has been one of the primary obstacles facing healthcare professionals in their attempt to treat cancer patients. Cancer is at the forefront of disease states which have proved difficult to understand and treat due to each patient’s unique genetic makeup and… |
![]() |
Safety and efficacy of a new drug: sofosbuvir/velpatasv...
October 1, 2017 - Clinical , Featured By: Shireen Farzadeh, PharmD Candidate c/o 2019 – Sofosbuvir/velpatasvir/voxilaprevir (Vosevi®) is the first pangenotypic fixed-dose combination tablet that includes 400 mg of sofosbuvir, a Hepatitis C virus (HCV) nucleotide analog, 100 mg of velpatasvir, an HCV NS5A inhibitor, and 100 mg of voxilaprevir, an HCV NS3/4A protease inhibitors.1,2 In the interest of brevity, sofosbuvir/velpatasvir/voxilaprevir will… |
![]() |
The future of pharmacy at our fingertips...
October 1, 2017 - Featured , Professional Advice / Opinions By: Gabrielle Flavoni, PharmD Candidate c/o 2018 – Pharmacists have always been deemed one of the most accessible health care providers in the community, especially to those who cannot often travel long distances. Over the years, many retail pharmacies began offering delivery services for prescription medications, specifically for the elderly and disabled. However, delivery services… |
![]() |
The opioid epidemic: a national crisis...
October 1, 2017 - Featured , In the News / Politics By: Katharine Russo, PharmD Candidate c/o 2021 – The DEA announced in August 2017 that 2018 would bring strict manufacturing reductions to commonly prescribed schedule II opioid painkillers. As the opioid epidemic continues to take countless lives, the government, including President Donald Trump are cracking down on regulations. Under this directive, there will be a… |
![]() |
The role of evolocumab (Repatha ®) in the treatment of...
October 1, 2017 - Featured , In the News / Politics By: Katie Lee, PharmD Candidate c/o 2019 – In 2015, FDA approved evolocumab (Repatha ®), a human monoclonal antibody of the PCKSK9 (proprotein convertase subtilisin kexin type 9) inhibitor class.1 Evolocumab is used to treat adult patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who need further lowering of their LDL-C levels,… |
![]() |
White coat ceremony: a rite of passage...
October 1, 2017 - Events , Featured By: Katharine Russo, PharmD Candidate c/o 2021 – A traditional rite of passage, the 18th Annual Pharmacy White Coat Ceremony on October 21st, 2017 marked a student’s progression into the rigorous academic and professional years of pharmacy school at St John’s University College of Pharmacy and Health Sciences. As Senior Associate Dean for Pharmacy Dr.… |